FDA approves Zepbound KwikPen, one device holding four weekly doses

Eli Lilly announced on Feb. 23, 2026 that the FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose, single-patient-use KwikPen, which delivers a full month of treatment in one device ^[1]. With a prescription, patients choosing self-pay through LillyDirect can buy any Zepbound dose in either a KwikPen or a single-dose vial at the same price, starting at $299 per month for the 2.5 mg dose ^[1]. The company said the KwikPen is available by prescription now through LillyDirect ^[1].

Prices on LillyDirect's Zepbound page run from $299 a month for 2.5 mg and $399 a month for 5 mg, up to $449 a month for the 7.5 mg, 10 mg, 12.5 mg and 15 mg doses when the prescription is refilled within 45 days ^[3]. If a 7.5 mg or higher prescription is not refilled in that window, LillyDirect lists higher prices: $499 for 7.5 mg and $699 for each of 10 mg, 12.5 mg and 15 mg ^[3]. Each KwikPen listing states that a pen needle purchase is required ^[3]. By comparison, LillyDirect's single-dose Zepbound pen listings say the needle is included in each pen ^[3].

The device changes the routine in two ways. The KwikPen must be primed before every injection, the same as insulin pens, according to Rx Radio; semaglutide pens such as Ozempic and Wegovy need priming only once with a new pen ^[2]. Lilly's safety information says the KwikPen must not be shared with anyone else, even if the pen needle has been changed, because of infection risk ^[1]. Rx Radio also reported that the KwikPen is currently available only through LillyDirect Pharmacy, not through community pharmacies ^[2].

Lilly said Zepbound is the most prescribed injectable obesity-management medication in the United States ^[1], and Rx Radio cited IQVIA National Prescription Audit data in saying tirzepatide was the most prescribed weight management medication in 2025 ^[2]. Lilly said more than 1 million patients accessed Lilly treatments through LillyDirect in 2025, and one of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials that year ^[1].

On effectiveness, Lilly cited SURMOUNT-1, where adults taking Zepbound 15 mg lost an average of 20.9% of body weight over 72 weeks, compared with 3.1% for placebo ^[1]. In SURMOUNT-5, an open-label study, people taking Zepbound lost an average of 50 pounds (20.2%) versus 33 pounds (13.7%) for injectable Wegovy (semaglutide); Lilly noted the study was less rigorous than a blinded trial ^[1]. Zepbound is approved in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg doses, and Lilly states the 2.5 mg dose is a starting dose only, not an approved maintenance dose ^[1][3].

Why it matters for patients

The practical benefit is fewer devices: one pen covers four weekly injections instead of four separate pens per month, at the same self-pay price as vials for each dose ^[1][2]. Two extra steps come with it. Patients have to prime the KwikPen before every dose, which is different from how semaglutide pens are primed ^[2], and they have to get pen needles separately, since LillyDirect labels them as a required purchase for each KwikPen strength ^[3]. Neither source states what those needles cost or whether insurance covers them.

Access is also narrower for now. Rx Radio reported the KwikPen is available only through LillyDirect Pharmacy ^[2], though LillyDirect's KwikPen listings say select insurance is accepted as well as self-pay ^[3]. LillyDirect separate single-dose pen listings for insured patients show prices as low as $25 a month for up to a three-month prescription, with governmental beneficiaries excluded ^[3]. LillyDirect also points eligible Medicare Part D patients with a KwikPen prescription for weight management to a Medicare GLP-1 Bridge program ^[3].

Whether the KwikPen replaces the four single-dose pens or simply adds a choice has not been disclosed, and Lilly has not said whether other pharmacies will carry it. Those points have not been reported.